Sherbrooke Park Advisers’s AbbVie ABBV Stock Holding History

Sherbrooke Park Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,862	Closed	-$663K	–	183
2025 Q3	$663K	Sell	2,862 -199	-7%	-$40.5K	0.31%	93
2025 Q2	$568K	Buy	+3,061	New	+$569K	0.25%	139
2023 Q3	–	Sell	-5,000	Closed	-$674K	–	494
2023 Q2	$674K	Buy	+5,000	New	+$733K	0.35%	103

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Sherbrooke Park Advisers's ABBV Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of AbbVie (ABBV) in Q4 2025, closing a stake of 2,862 shares — an estimated $663K sold.

Sherbrooke Park Advisers first reported a position in ABBV in Q2 2023 and held it in 3 quarters. The position peaked at $674K in Q2 2023. 4,148 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Sherbrooke Park Advisers reported no remaining AbbVie position as of Q4 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 2,862 AbbVie shares in Q4 2025, an estimated $663K.
Sherbrooke Park Advisers first reported a position in AbbVie in Q2 2023 and held it in 3 quarters.
Sherbrooke Park Advisers's AbbVie position peaked at $674K in Q2 2023.
4,148 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.